

1648 Isw

# Attorney Docket No. 2300-16464 (PP 16464.004)

**PATENT** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 6/15/04.

Denise Vaillancourt

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Vajdy et al.

Serial No.: 10/051,749

Examiner: T. Brown

Confirmation No.: 5494

Art Unit: 1648

Filed: January 14, 2002

For: NUCLEIC ACID MUCOSAL IMMUNIZATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

[X]	the IDS is required.		
[]	In accordance with 37 C.F.R. §1.97(c), also enclosed is:		
	[]	the fee of \$180.00 as	s set forth in 37 C.F.R. §1.17(p); or
	[]	a statement as specif	ied in 37 C.F.R. §1.97(e).
[]	In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17( are also enclosed.		
П	Check No.	in the amount of \$	for the total fee is attached

- [X] A return receipt postcard is also enclosed.
- [] Please charge \$\_\_\_\_ to Deposit Account No. 18-1648 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Dated: June 15,04

Respectfully submitted,

Michael Moran Chiron Corporation Intellectual Property- R440 P.O. Box 8097 Emeryville, CA 94662-8097

Tel: (510) 923-2969 Fax: (510) 655-3542 By:

Dahna S. Pasternak Reg. No. 41,411

#### Attorney Docket No. 2300-16464 (PP 16464.004)

**PATENT** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 6/15/04

Denise Vaillancourt

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Vajdy et al.

Serial No.: 10/051,749

Examiner: T. Brown

Confirmation No.: 5494

Art Unit: 1648

Filed: January 14, 2002

For: NUCLEIC ACID MUCOSAL IMMUNIZATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

[X]	Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.	
[]	No copies of the publications listed on the attached Form PTO/SB/08A a being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.	
[]	Publication(s) listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to application serial no and mailed on	

	[]	Enclosed is a copy of a non-English public of the M.P.E.P., Applicant submits the atta examination report, which cites such non-	ached foreign search or	
	[] Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-English publication.			
	[]	Enclosed is an explanation of non-English English translation is not available.	publication(s) for which an	
	[]	Enclosed is an English translation of non-lin the attached Form PTO/SB/08A.	English publication(s)cited	
	[]	Enclosed is a copy of pending patent Appl	ication Serial No	
time pe		formation Disclosure Statement is filed with	thin any one of the following	
	[]	[] within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);		
	[]	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;		
	[X]	before the mailing date of a first office act	ion on the merits; or	
	[] before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.			
	It is res	spectfully requested that the Examiner cons	sider the above-noted	
inform	ation ar	nd return an initialed copy of the attached F	orm PTO/SB/08A to the	
unders	igned.			
Dated:	Ju	ne 15, 2004	Respectfully submitted,	
Michae	el Mora	n		
	Corpo			
	ox 8097	operty- R440		
- · · · D	J. 1 0 0 7 1			

By:

Dahna S. Pasternak Reg. No. 41,411

Emeryville, CA 94662-8097

Tel: (510) 923-2969

Fax: (510) 655-3542

O P E JOP les	sse type a plus sign (+) inside this box →	+
JUN 1 8 JULY	Substitute for form 1449A/PTO INFORMATION DISCLOS	SURI

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of

Complete if Known			
Application Number	10/051,749	_	
Filing Date	January 14, 2002		
First Named Inventor	Vajdy et al		
Group Art Unit	1648		
Examiner Name	T. Brown	_	
Attorney Docket Number	2300-16464 (PP 16464.004)		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Montagnier et al., "A NEW HUMAN T-LYMPHOTROPIC RETROVIUS: CHARATERIZATION AND POSSIBLE ROLE IN LYMPHADENOPATHY AND ACQUIRED IMMUNE DEFICIENCY SYNDROMES" <u>HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS</u> , Gallo, Essex & Gross eds., Section 5, pp. 363-379, Cold Spring Harbor Laboratory: US (1984)	
•		0.5 (1964)	
_			

Examiner	Date	
Signature	Considered	
4.8		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.